Jiri Minarik

17PUBLICATIONS
92CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical mycologyPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jun 12, 2026
Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

|Dec 27, 2025
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.

Gurdeep Parmar, Marcelo Capra, Fernanda Seguro

|Jun 03, 2025
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.

Sikander Ailawadhi, Ivan Špička, Andrew Spencer

|Oct 11, 2024
Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry.

Ludmila Muronova, Ondrej Soucek, David Zihala

|Dec 11, 2022
Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma.

Monika Vlachová, Jana Gregorová, Petra Vychytilová-Faltejsková

|Dec 11, 2022
Immunomodulatory Agents for Multiple Myeloma.

Jiří Minařík, Sabina Ševčíková

Pageof 3

Frequent Collaborators

7 joint publications

Martin Stork

6 joint publications

Tomas Jelinek

5 joint publications

Roman Hajek

4 joint publications

Sabina Ševčíková